The company's technology is based on modifying naturally occurring antibiotics called pyrrolobenzodiazepines (PBDs) to create potent therapeutic agents that bind to the minor groove of DNA and alkylate it. Spirogen's product portfolio includes a C2 unsaturated PBD dimer, a PBD dimer prodrug, and an achiral analogue of duocarmycin. In addition to these molecules, Spirogen also offers antibody drug conjugate (ADC) technology that attaches potent anticancer agents to antibodies for targeted delivery to cancer cells. Founded in 2000, Spirogen is privately funded and has 18 employees.